Teriparatide Superior to Risedronate in the VERO Trial Save
Lancet reports that in a study teriparatide with risedronate, post-menopausal women with severe osteoporosis had significantly fewer new vertebral and clinical fractures on teriparatide comared to those receiving risedronate.
This trial is one of the first to compare osteoporosis drugs with incident fractures as the primary outcome.
Post-menopausal women (n=680) with more than one severe vertebral fracture and a BMD T score of less than or equal to −1·50 were enrolled to receive 20 μg of teriparatide (TER) daily or 35 mg of oral risedronate (RIS) once weekly for 24 months. The primary outcome was new radiographic vertebral fractures.
After 24 months, fewer new vertebral fractures (5·4%) were seen in the TER patients vs. RIS group (12·0%) (p<0·0001).
Clinical fractures were also decreased in the TER patients (4·8% vs. 9·8%). Non-vertebral fragility fractures were not significant but were also lowere (4% vs 6·1%).
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.